ATE342054T1 - Verfahren und zusammansetzung zur behandlung von krebs - Google Patents

Verfahren und zusammansetzung zur behandlung von krebs

Info

Publication number
ATE342054T1
ATE342054T1 AT00922237T AT00922237T ATE342054T1 AT E342054 T1 ATE342054 T1 AT E342054T1 AT 00922237 T AT00922237 T AT 00922237T AT 00922237 T AT00922237 T AT 00922237T AT E342054 T1 ATE342054 T1 AT E342054T1
Authority
AT
Austria
Prior art keywords
composition
lapachone
beta
administration
treating cancer
Prior art date
Application number
AT00922237T
Other languages
English (en)
Inventor
Arthur B Pardee
Chiang J Li
You-Zhi Li
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE342054T1 publication Critical patent/ATE342054T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
AT00922237T 1999-04-14 2000-04-14 Verfahren und zusammansetzung zur behandlung von krebs ATE342054T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12926199P 1999-04-14 1999-04-14

Publications (1)

Publication Number Publication Date
ATE342054T1 true ATE342054T1 (de) 2006-11-15

Family

ID=22439161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922237T ATE342054T1 (de) 1999-04-14 2000-04-14 Verfahren und zusammansetzung zur behandlung von krebs

Country Status (8)

Country Link
US (3) US6664288B1 (de)
EP (1) EP1181013B1 (de)
JP (2) JP2002541200A (de)
AT (1) ATE342054T1 (de)
CA (1) CA2369303A1 (de)
DE (1) DE60031268T2 (de)
ES (1) ES2273688T3 (de)
WO (1) WO2000061142A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP1386922B1 (de) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthese von Epitholonen, Zwischenprodukte, Analoga und ihre Verwendung
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US7820718B1 (en) * 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US20040209942A1 (en) * 2002-07-17 2004-10-21 Li Chiang J. Activated checkpoint therapy and methods of use thereof
ES2273688T3 (es) * 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
MXPA03003011A (es) * 2000-10-05 2003-07-14 George Q Daley Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
AU2002234165A1 (en) 2000-11-03 2002-05-27 Tularik, Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US7070797B2 (en) 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US20020169135A1 (en) * 2000-11-07 2002-11-14 Pardee Arthur B. Method of treating hematologic tumors and cancers
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
US20030212147A1 (en) * 2001-07-12 2003-11-13 Chung Sum Man Stephen Enzyme activated chemotherapy of liver cancer
US7074824B2 (en) 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6962944B2 (en) * 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
AU2007200677B2 (en) * 2002-01-14 2009-10-29 Novartis Ag Combinations comprising epothilones and anti-metabolites
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
US6890950B2 (en) 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
AU2003296878A1 (en) * 2002-05-20 2004-12-13 Kosan Biosciences, Inc. Methods to administer epothilone d
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
BR0315169A (pt) * 2002-10-09 2005-08-23 Kosan Biosciences Inc Referência cruzada a pedidos de patente relacionados
JP2006508147A (ja) * 2002-11-18 2006-03-09 アルキュール, インコーポレイテッド 新規ラパコン化合物およびその使用方法
US7361691B2 (en) * 2002-12-02 2008-04-22 Arqule, Inc. Method of treating cancers using β-lapachone or analogs or derivatives thereof
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2005053682A2 (en) 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
GB2423526A (en) * 2003-11-26 2006-08-30 Amadeo Parissenti Use of isogenic drug-resistant cell lines to determine the sequence of chemotherapeutic drug treatment
CA2556823A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of lung cancer
CA2555950A1 (en) 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
WO2005082355A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treatment of colon cancer
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006020719A2 (en) 2004-08-11 2006-02-23 Arqule, Inc. Aminoacid conjugates of beta - lapachone for tumor targeting
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
WO2006078503A2 (en) 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
RU2449788C2 (ru) * 2006-04-05 2012-05-10 Новартис Аг Комбинации терапевтических агентов для лечения рака
JP2009538298A (ja) * 2006-05-26 2009-11-05 アークル インコーポレイテッド 新規のラパコン化合物およびその使用方法
TW200824692A (en) 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
BRPI0810717A2 (pt) 2007-04-30 2016-05-24 Arqule Inc sulfonato hidroxi de composto de quinona e seus usos
WO2009051752A1 (en) 2007-10-16 2009-04-23 Arqule, Inc. Novel lapachone compounds and methods of use thereof
US7808078B2 (en) * 2008-08-26 2010-10-05 Sanyo Electric Co., Ltd. Semiconductor device and manufacturing method thereof
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
KR20130027080A (ko) 2010-01-06 2013-03-14 에리코, 조셉, 피. 표적화된 약물 개발 방법 및 조성물
TR201807363T4 (tr) 2010-09-22 2018-06-21 Univ Texas Hedefleyici nqo1 i içeren kanser tedavi yöntemleri.
US20140161720A1 (en) * 2011-05-26 2014-06-12 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
BRPI1106509A2 (pt) * 2011-10-25 2013-11-19 Universidade Federal Do Rio De Janeiro Ufrj Uso das pironofatoquinona como antiviral; composição farmacêutica contendo as piranonaftoquinonas; medicamento contendo as piranonaftoquinonas para tratamento de infecções causadas por virus da dengue
CN104971351A (zh) * 2014-04-08 2015-10-14 清华大学 药物组合物及其应用
US10537545B2 (en) 2015-07-20 2020-01-21 Rutgers, The State University Of New Jersey Ceramide derivatives as anticancer agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
ES2273688T3 (es) * 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.

Also Published As

Publication number Publication date
JP2002541200A (ja) 2002-12-03
CA2369303A1 (en) 2000-10-19
WO2000061142A1 (en) 2000-10-19
EP1181013A4 (de) 2004-07-07
EP1181013B1 (de) 2006-10-11
US6664288B1 (en) 2003-12-16
ES2273688T3 (es) 2007-05-16
US20050171031A1 (en) 2005-08-04
US6875745B2 (en) 2005-04-05
JP2009051841A (ja) 2009-03-12
DE60031268T2 (de) 2007-05-24
EP1181013A1 (de) 2002-02-27
US20040087610A1 (en) 2004-05-06
DE60031268D1 (de) 2006-11-23

Similar Documents

Publication Publication Date Title
EP1181013A4 (de) Verfahren und zusammansetzung zur behandlung von krebs
ATE310506T1 (de) Biodegradierbare polyphosphoester- zusammensetzungen zur behandlung von ovarialkrebs
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
ATE421322T1 (de) Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
GB0305152D0 (en) Organic compounds
EP1622608A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
GEP20043322B (en) C7 Ester Substituted Taxanes as Antitumor Agents, Pharmaceutical Compositions Containing the Same and Use Thereof for Inhibiting Tumors
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
WO2002058694A3 (en) Method of treating hematologic tumors and cancers using beta lapachone
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
DK1056704T3 (da) Antitumormidler
DE60334711D1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
DE69815100D1 (de) Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ATE359800T1 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
BRPI0410026A (pt) derivados de 3-amino-croman quinolina
MXPA02010813A (es) Fosforamidatos de bis-(n,n'-bis-(2-haloetil)amino) como agentes antitumor.
WO2005102997A8 (en) 3,4-disubstituted maleimides for use as vascular damaging agents
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE602004014125D1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
DE60305520D1 (de) 2" oxo-voruscharin und derivaten
HK1154859A1 (zh) 用於治療癌症的異吲哚啉化合物

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties